• Product NameVCMMAE
• Brief DescriptionInhibitors
• Purification100.00%
• Biological ActivityVcMMAE is a drug-linker conjugate for ADC with potent antitumor activity by using the anti-mitotic agent, monomethyl auristatin E (MMAE), linked via the lysosomally cleavable dipeptide, valine-citrulline (vc).
• Target NameMicrotubule Associated inhibitor
• CAS No. 646502-53-6
• Calculated MW 1316.65
• Formulation C68H105N11O15
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:cancer
  SMILES:CC[C@H](C)[C@@H]([C@@H](CC(=O)N1CCC[C@H]1[C@@H]([C@@H](C)C(=O)N[C@H](C)[C@H](C2=CC=CC=C2)O)OC)OC)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)OCC3=CC=C(C=C3)NC(=O)[C@H](CCCNC(=O)N)NC(=O)[C@H](C(C)C)NC(=O)CCCCCN4C(=O)C=CC4=O
  Pathways:Cytoskeletal Signaling
  Receptor:Microtubule/Tubulin
  Boling pt:
  Melting pt:
  Solubility:DMSO: 54 mg/mL VcMMAE is dissolved in DMSO and then diluted with 0.9% NaCl
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting